Yu Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu Liu has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiang Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
9 shared publications - Shaowei Qiu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 shared publications - Yihan Mei
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
9 shared publications - Fan Ding
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications - Haiyan Xing
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications - Junli Mou
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 8 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1309-1322
Single‐cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia
Summary: The t(8;21)(q22;q22) translocation is one of the most recurrent cytogenetic aberrations in acute myeloid leukaemia (AML). While most patients achieve complete remission, approximately 40% of them still relapse. Early identification and elimination of leukaemia clones with relapse potential could improve prognosis for t(8;21) AML patients. Here, through single‐cell RNA sequencing, we characterized the intra‐tumoral heterogeneity of t(8;21) AML and identified haematopoietic stem cell (HSC)‐like subset as the most quiescent and primitive subgroup among all leukaemia cell populations. Further investigations revealed IKZF2 as the master regulator for HSC‐like subset. Notably, IKZF2 was upregulated in t(8;21) AML compared with other AML subtypes and was specifically targeted by AML1‐ETO. Using primary samples and mouse models, we verified the high enrichment of IKZF2 in primitive and quiescent leukaemic cells. Moreover, IKZF2 knockout hindered the accumulation of aberrant stem cells driven by AML1‐ETO and promoted cellular differentiation both in vitro and in vivo. These facilitate a better understanding of the leukaemia cell heterogeneity in t(8;21) AML and unveil IKZF2 as a potential target for improving current treatment strategies.
- 8 August 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1309-1322
Single‐cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia
Summary: The t(8;21)(q22;q22) translocation is one of the most recurrent cytogenetic aberrations in acute myeloid leukaemia (AML). While most patients achieve complete remission, approximately 40% of them still relapse. Early identification and elimination of leukaemia clones with relapse potential could improve prognosis for t(8;21) AML patients. Here, through single‐cell RNA sequencing, we characterized the intra‐tumoral heterogeneity of t(8;21) AML and identified haematopoietic stem cell (HSC)‐like subset as the most quiescent and primitive subgroup among all leukaemia cell populations. Further investigations revealed IKZF2 as the master regulator for HSC‐like subset. Notably, IKZF2 was upregulated in t(8;21) AML compared with other AML subtypes and was specifically targeted by AML1‐ETO. Using primary samples and mouse models, we verified the high enrichment of IKZF2 in primitive and quiescent leukaemic cells. Moreover, IKZF2 knockout hindered the accumulation of aberrant stem cells driven by AML1‐ETO and promoted cellular differentiation both in vitro and in vivo. These facilitate a better understanding of the leukaemia cell heterogeneity in t(8;21) AML and unveil IKZF2 as a potential target for improving current treatment strategies.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 12 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (24) , 4233-4245
Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis. Significance: Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 12 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (24) , 4233-4245
Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis. Significance: Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.